Inflammation and CFTR: Might neutrophils be the key in cystic fibrosis?

Mediators of Inflammation

Volumn 8, Issue 1, 1999, Pages 7-11

  Witko Sarsat, V ^a   Sermet Gaudelus, I ^b   Lenoir, G ^b   Descamps Latscha, B ^a  

^a INSERM   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Cystic fibrosis; Cystic fibrosis transmembrane regulator; Inflammation; Neutrophils

Indexed keywords

TRANSMEMBRANE CONDUCTANCE REGULATOR;

BRONCHITIS; CYSTIC FIBROSIS; GENE EXPRESSION; GENE MUTATION; HUMAN; INFLAMMATORY DISEASE; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032914535     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359990658     Document Type: Review

References (47)

1. 1. Boat TF, Welsh MJ, Beaudet AL. Cystic fibrosis. In: Scriver R, Beaudet AL, Ly WS, Valle D, eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989: 2649-2680.
2. 2. Cantin A. Cystic fibrosis lung inflammation: early, sustained and severe. Am J Respir Crit Care Med 1995; 151: 939-941.
3. 3. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-1073.
4. 4. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993; 73: 1251-1254.
5. 5. Stern R. The diagnosis of cystic fibrosis. New Engl J Med 1997; 336: 487-491.
6. 6. Friend PA. Pulmonary infection in cystic fibrosis. J Infect Dis 1986; 13: 55-72.
7. 7. Fiel SB. Clinical management of pulmonary disease in cystic fibrosis. Lancet 1993; 341: 1070-1074.
8. 8. Baltimore RS, Mitchell M. Immunologic investigations of mucoid strains of Pseudomonas aeruginosa: comparison of susceptibility to opsonic antibody in mucoid and non-mucoid strains. J Infect Dis 1980; 141: 238-247.
9. 9. Pier GB, Grout M, Zaidi TS. Cystic fibrosis transmembrance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA 1997; 4: 12088-12093.
10. 10. Khan TZ, Wagner JS, Bost T, Martinez J, Accurso FJ, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995; 151: 1075-1084.
11. 11. Regelmann WE, Siefferman CM, Herron JM, Elliott GR, Clawson CC, Gray BH. Sputum peroxidase activity correlates with the severity of lung disease in cystic fibrosis. Pediatr Pulmonol 1995; 19: 1-9.
12. 12. Klebanoff SJ. Oxygen metabolites from phagocytes. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: Basic Principles and Clinical Correlates. New York: Raven Press, 1992: 541-589.
13. 13. Lehrer RI, Ganz T. Antimicrobial polypeptides of human neutrophils. Blood 1990; 76: 2169-2181.
14. 14. Richman-Eisenstat JB, Jorens PG, Hébert CA, Ueki I, Nadel JA. Interleukin-8: an important chemoattractant in sputum of patients with chronic inflammatory airway diseases. Am J Physiol 1993; 264: L413-L418.
15. 15. Suter S, Schaad UB, Roux L, Nydegger UE, Waldvogel FA. Granulocyte neutral proteases and Pseudomonas elastase as possible causes of airway damage in patients with cystic fibrosis. J Infect Dis 1984; 149: 523-531.
16. 16. Goldstein W, Döring G. Lysosomal enzymes from polymorphonuclear leukocytes and proteinase inhibitors in patients with cystic fibrosis. Am Rev Respir Dis 1986; 134: 49-56.
17. 17. Witko-Sarsat V, Halbwachs-Mecarelli L, Schuster A, Nusbauh P, Ueki I, Canteloup S, Lenoir G, Descamps-Latscha B, Nadel JA. Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum. Am J Resp Cell Mol Biol 1998; 20: in press.
18. 18. Birrer P, McElvaney NG, Rudeberg A, et al. Protease-antiprotease imbalance in the lungs of children with cystic fibrosis. Am J Respir Crit Care Med 1994; 150: 207-213.
19. 19. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM. Human beta-defensin-1 is a salt sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell 1997; 88: 553-560.
20. 20. Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT, Descamps-Latscha B. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am J Respir Crit Care Med 1995; 152: 1910-1916.
21. 21. Bonfield TL, Panuska JR, Konstan MW, et al. Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 1995; 152: 2111-2118.
22. 22. Prince A. Activation of NFkB and IL-8 transcription in cells with CFTR mutations. Pediatr Pulmonol 1998; Suppl 17: 103.
23. 23. Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. J Clin Invest 1998; 102: 1200-1207.
24. 24. Hansson GC. Cystic fibrosis and chloride-secreting diarrhoea letter. Nature 1988; 333: 711.
25. 25. Davis PB, Vargo K. Pulmonary abnormalities in obligate heterozygotes for cystic fibrosis. Thorax 1987; 42: 120-125.
26. 26. Sato K, Sato F Variable reduction in beta-adrenergic sweat secretion in cystic fibrosis heterozygotes. J Lab Clin Med 1988; 111: 511-518.
27. 27. Prince A. The CFTR advantage-capitalizing on a quirk of fate. Nature Med 1998; 4: 663-664.
28. 28. Gabriel SE, Brigman KN, Koller BH, Boucher RC, Stutts MJ. Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 1994; 266: 107-109.
29. 29. Yoshimura K, Nakamura H, Trapnell BC, et al. Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res 1991; 19: 5417-5423.
30. 30. Witko-Sarsat V, Allen RC, Paulais M, Bessou G, Lenoir G, Descamps-Latscha B. Disturbed myeloperoxidase-dependent activity of neutrophils in cystic fibrosis homozygotes and heterozygotes, and its correction by amiloride. J Immunol 1996; 157: 2728-2735.
31. 31. Grinstein S, Furuya W, Biggar WD. Cytoplasmic pH regulation in normal and abnormal neutrophils. J Biol Chem 1986; 261: 512-514.
32. 32. Rosengren S, Henson PM, Worthern GS. Migration-associated volume changes in neutrophils facilitates the migration process. Am J Physiol 1994; 267: C1623-C1627.
33. 33. Russell KJ, McRedmond J, Mukherji N, et al. Neutrophil adhesion molecule surface expression and responsiveness in cystic fibrosis. Am J Respir Crit Care Med 1998; 157: 756-761.
34. 34. Witko-Sarsat V, Nguyen AT, Descamps-Latscha B. Immunomodulatory role of phagocyte-derived chloramines involving lymphocyte glutathione. Med Inflamm 1993; 2: 235-241.
35. 35. Hoof T, Demmer A, Hadam MR, Riordan JR, Tümmler B. Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1. J Biol Chem 1994; 269: 20575-20583.
36. 36. Wei LY, Hoffman MM, Roepe PD. Altered pH regulation in 3T3/CFTR clones and their chemotherapeutic drug-selected derivatives. Am J Physiol 1997; 272: C1642-C1653.
37. 37. Barasch J, Kiss B, Prince A, Saiman L, Gruenert D, Al-Awqati Q. Defective acidification of intracellular organelles in cystic fibrosis. Nature 1991; 352: 70-73.
38. 38. Kim JH, Grinstein S, Cotton CU. Measurement of Golgi pH in epithelial cells from normal and CFTR null mice. Pediatr Pulmonol 1998; Suppl 17: 211
39. 39. Linsdell P, Hanrahan JW. Glutathione permeability of CFTR. Am J Physiol 1998; 275: C323-326.
40. 40. Witko-Sarsat V, Halbwachs-Mecarelli L, Sermet-Gaudelus I, Bessou G, Lenoir G, Allen RC, Descamps-Latscha B. Priming of blood neutrophils in cystic fibrosis children: correlation between functional and phenotypic expression of opsonin receptors pre-and post-PAF priming. J Infect Dis 1999; 179: 151-162.
41. 41. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-854.
42. 42. Stockley RA. The role of proteinases in the pathogenesis of chronic bronchitis. Am J Respir Crit Care Med 1994; 150: S109-S113.
43. 43. McElvaney NG, Hubbard R, Birrer P, et al. Aerosol alpha-1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-394.
44. 44. McElvaney NG, Nakamura H, Birrer P, et al. Modulation of airway inflammation in cystic fibrosis. In vivo suppression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoproteinase inhibitor. J Clin Invest 1992; 90: 1296-1301.
45. 45. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322: 1189-1194.
46. 46. Lallemand JY, Stoven V, Annereau JP, Boucher J, Blanquet S, Barthe J, Lenoir G. Induction by antitumoral drugs of proteins that functionally complement CFTR: a novel therapy for cystic fibrosis? Lancet 1997; 350: 711-712.
47. 47. Sermet-Gaudelus I, Stoven V, Annereau JP, Witko-Sarsat V, Reinert P, Guyot M, Descamps-Latscha B, Lallemand JY, Lenoir G. Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report. Med Inflamm 1999; 8: 13-15.